GFPT2

Across TCGA pan-cancer cohorts, GFPT2 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated GFPT2 data layer compared with 11 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher GFPT2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated GFPT2 expression acts as an unfavorable survival marker, although some lineages such as UVM and MESO show a favorable association.

KIRC, UVM, and MESO are the cancer types where GFPT2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.526	0.724	<.001	127	view →
UVM	DFS	Median	All	0.889	0.593	<.001	76	view →
MESO	OS	Tertile	IV	1.000	0.353	.003	58	view →
BLCA	OS	Tertile	All	0.557	0.707	.003	54	view →
KICH	DFS	Tertile	III,IV	0.033	1.000	.002	51	view →
THCA	OS	Tertile	II,III,IV	0.781	1.000	.003	38	view →
HNSC	OS	Median	All	0.708	0.793	.005	38	view →
KIRP	DFS	Median	III,IV	0.101	0.555	.005	31	view →
CESC	DFS	Tertile	All	0.750	0.885	.002	28	view →
OV	DFS	Median	All	0.487	0.595	.002	28	view →
DLBC	DFS	Quartile	III,IV	0.923	0.184	.006	28	view →
LUSC	OS	Tertile	All	0.736	0.832	.012	27	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

GFPT2–KIRC (DFS)

Open the KIRC breakdown →